Surrogate marker and design of Calliditas Therapeutics’ IgA nephropathy Phase 3 study agreed with the FDA November 20, 2017 09:00 CET Non Regulatory Read more
Pharmalink strengthens its management team. Appoints new Chief Financial Officer and head of communications August 15, 2017 15:40 CET Non Regulatory Read more
Positive Phase 2b Trial of Pharmalink’s Nefecon in Primary IgA Nephropathy presented at Leading Kidney Disease Conference July 4, 2017 15:39 CET Non Regulatory Read more
Positive Phase 2b Trial of Pharmalink’s Nefecon in IgA Nephropathy Selected for Presentation at Leading Kidney Disease Conference May 31, 2017 15:38 CET Non Regulatory Read more
Pharmalink AB announces the appointment of a new Chief Executive Officer May 18, 2017 15:38 CET Non Regulatory Read more
Positive results of Phase 2b Clinical Trial of Pharmalink’s Nefecon in Primary IgA Nephropathy published in The Lancet March 29, 2017 15:36 CET Non Regulatory Read more
